Incyte Corporation: Vega Therapeutics acquisition is a good strategic fit

Research evidence excerpt

Incyte Corporation: Vega Therapeutics acquisition is a good strategic fit

Accessible version

Incyte Corporation

Vega Therapeutics acquisition is a good

strategic fit

Maintain Rating: BUY | PO: 124.00 USD | Price: 102.38 USD

Breaking News 08 June 2026

Equity• INCY is acquiring Vega Therapeutics for up to $2bn, including $1.25bn upfront,

bringing in phase 3 asset for VWD Tazeen Ahmad

Research Analyst

• We think the deal makes sense as it fits well with the company's long-term growth BofAS

strategy and allows for further deals +1 646 855 4236

tazeen.ahmad@bofa.com

Daniel Giraldo

INCY is acquiring Vega Therapeutics for up to $2bn ResearchBofAS Analyst

Incyte (INCY) announced the acquisition of Vega Therapeutics, a subsidiary of Star daniel.giraldoperez@bofa.com

Therapeutics (private), for up to $2bn, including $1.25bn upfront. Star Therapeutics is Jeremiah Lorentz

focused on developing antibody treatments for hematologic and immunologic disorders, BofAS

and the acquisition brings in its lead program, VGA309 in Von Willebrand Disease (VWD; jeremiah.lorentz@bofa.com

bleeding disorder), already in phase 3. We highlight INCY management has signaled they Wesley Yon

are looking to acquire late-stage assets as part of the long-term growth strategy (see BofAS

our ASCO takeaways). The deal fits well within one of their key areas of focus, wesley.yon@bofa.com

hematology. Management has commented they have $7-8bn available, so the $1.25bn

upfront payment would not stress the balance sheet and would allow them to continue

exploring additional acquisitions. Overall, we view this as a strong fit with the company’s Stock Data

strategic priorities and look for further details on the deal expected to close in 3Q. We

maintain our Buy with $124 PO. Price 102.38 USD

Price Objective 124.00 USD